Compare Bank of America Corp (BAC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Bank of America CorpTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Bank of America Corp vs Neurocrine Biosciences Inc — how do they compare? Bank of America Corp trades at $63.98 (market cap $447.54B), while Neurocrine Biosciences Inc trades at $156.62 (market cap $16.46B). The key difference: Bank of America Corp is far larger — about 27.2× Neurocrine Biosciences Inc's market cap, and Bank of America Corp pays a 2% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	BAC	NBIX
Market Cap	$447.54B	$16.46B
Volume	55,637,172	—
Sector	Financials	Health
52-Week High	$64.00	$185.50
52-Week Low	$46.72	$123.10
Dividend Yield	2%	—
Enterprise Value	—	$16.48B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of America Corp

Bank of America (BAC) trades at $63.86, up 1.09% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and revenue growth to $113.10B in 2025. Analyst consensus is strongly positive, with a $67.36 price target and 35 buy ratings. Recent news highlights strategic partnerships and hiring initiatives, reinforcing growth prospects.

BAC presents a favorable investment opportunity driven by earnings beats, robust deposit franchise, and potential capital returns post-stress tests. Risks include interest rate sensitivity and macroeconomic volatility. The stock's current valuation at a P/E of 14.78 offers room for upside relative to historical averages, supported by institutional bullishness.

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BAC

Bank of America launches $250B initiative to boost US infrastructure and job growth by 2027PRNewsWire · 7 hours agoBullish Bank of America launches $250B initiative to fund U.S. infrastructure including data centers and energy projects.Fox Business · 7 hours agoBullish Bank of America stock hits record highs with strong analyst buy ratings and robust earnings growth.24/7 Wall Street · 1 day agoBullish View details →

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 5 hours agoBullish View details →

About Bank of America Corp

Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.